Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humansPK/PD and safety
Whats the main difference between KLOW and other peptide blends
In the spring of 2022, the Food and Drug Administration (FDA) approved tirzepatide for the management and treatment of T2DM, and it has also recently been approved in Europe
This medication became one of the first drugs in a class known as GLP-1 receptor agonists
[Google Scholar] Microbe-mitochondrion crosstalk and health: An emerging paradigm